Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Has FDA OK For Phase III Voclosporin Trialing In Lupus Nephritis

Executive Summary

Following consultations with the FDA, Canada's Aurinia Pharmaceuticals plans to run a single Phase III trial for voclosporin in lupus nephritis and then proceed to filing an NDA.

You may also be interested in...



New AURA Lupus Data Bode Well For Aurinia's Voclosporin In Future Phase III

Long-term data from the AURA-LV study in lupus nephritis show voclosporin is superior to standard of care, raising expectations for future Phase III success.

Aurinia Names CEO

Aurinia Pharmaceuticals Inc. has appointed Charles Rowland CEO, replacing Stephen Zaruby who will be resigning as the company's CEO and from its board of directors. Rowland was vice president and chief financial officer (CFO) of ViroPharma Inc. until it was acquired by Shire PLC. in 2014. Prior to this, he held various leadership positions at biotech and pharma companies and most recently was interim co-CEO, executive vice president, CFO for Endo Pharmaceuticals Inc. Previously Rowland held positions at Biovail Corp., Breakaway Technologies Inc., Pharmacia Corp., Novartis AG and Bristol-Myers Squibb.

Getting Its ACT Together: EXACT-Tx Raises NOK155m

EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel